Get the Stockscreener App
26.60
0.00%
0.0031
Bridgebio Pharma Inc stock is traded at $26.60, with a volume of 379.35K.
It is up +0.00% in the last 24 hours and up +4.40% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$26.60
Open:
$26.42
24h Volume:
379.35K
Relative Volume:
0.17
Market Cap:
$5.02B
Revenue:
$219.12M
Net Income/Loss:
$-453.82M
P/E Ratio:
-6.8197
EPS:
-3.9
Net Cash Flow:
$-419.68M
1W Performance:
+0.61%
1M Performance:
+4.40%
6M Performance:
-8.21%
1Y Performance:
-14.03%
1-Day Range:
$26.32
$27.08
1-Week Range:
$26.15
$28.20
52-Week Range:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
26.59 | 5.02B | 219.12M | -453.82M | -419.68M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.17 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.07 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.07 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.44 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Pharma (FRA:2CL) Price-to-Operating-Cash-Flow : (As of Dec. 01, 2024) - GuruFocus.com
The week in pharma: action, reaction and insight – week to November 29 - The Pharma Letter
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug - MSN
Intech Investment Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Soars After Drug Gets Nod in Rare Heart Condition - MSN
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - MSN
HC Wainwright Has Optimistic Outlook of BBIO FY2024 Earnings - MarketBeat
Research Analysts Offer Predictions for BBIO FY2024 Earnings - MarketBeat
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug - MSN
BridgeBio Pharma (FRA:2CL) Total Liabilities : €1,696.9 Mil (As of Sep. 2024) - GuruFocus.com
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby - Marketscreener.com
BridgeBio: Shares Surge as Attruby Gains FDA Approval; Slightly Raising Our Fair Value Estimate - Morningstar
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability - Morningstar
What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings? - MarketBeat
BridgeBio price target raised to $45 from $42 at BofA - Yahoo Finance
Eagle Asset Management Inc. Lowers Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Algert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Massachusetts Financial Services Co. MA Grows Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds - MSN
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer - MSN
FDA approves BridgeBio’s Attruby for ATTR-CM treatment - Indian Pharma Post
BridgeBio Pharma Receive FDA Nod for Attruby - Diagnostic and Interventional Cardiology
BridgeBio’s Attruby Could Benefit From ‘Best-Case’ Label, Lower Price - Citeline News & Insights
Health Care Up Amid Cyclical Bias -- Health Care Roundup - Marketscreener.com
Bridgebio, with FDA approval, faces Pfizer in ATTR - BioWorld Online
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race - FirstWord Pharma
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug - Investor's Business Daily
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY™ (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis - Yahoo Finance
Gold Down Over 3%; Rigetti Computing Shares Spike Higher - Benzinga
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - MedCity News
BridgeBio's SWOT analysis: genetic disease fighter's stock faces pivotal moment - Investing.com
BridgeBio stock retains Overweight; Piper Sandler highlights competitive pricing for Attruby - Investing.com
US FDA approves BridgeBio's drug for rare heart condition (Nov 22) - Reuters
BridgeBio stock remains Market Perform; BMO cites key milestone in regulatory progress - Investing.com
BridgeBio shares surge 25% on FDA approval of Attruby - Investing.com
FDA approves Palo Alto biotech's heart disease drug - The Business Journals
BridgeBio shares maintain buy rating on positive Attruby launch outlook - Investing.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up After Analyst Upgrade - MarketBeat
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday - Benzinga
BridgeBio Soars After Drug Gets Nod in Serious Heart Condition - MSN
BridgeBio price target raised to $48 from $45 at Scotiabank - TipRanks
BridgeBio shares retain Buy rating as H.C. Wainwright highlights Attruby FDA approval - Investing.com
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby - MarketWatch
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Yahoo Finance
Bank of America Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $45.00 - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $49.00 - MarketBeat
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy - FiercePharma
FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM - PMLiVE
BridgeBio gets FDA nod for Attruby to treat ATTR-CM patients - World Pharmaceutical Frontiers
BridgeBio Pharma Obtains FDA Approval of Attruby - Marketscreener.com
BBIO (BridgeBio Pharma) Long-Term Capital Lease Obligation : $5.8 Mil (As of Sep. 2024) - GuruFocus.com
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):